GlassScriptPhysician profile
Tabitha Hendrix Mullis
NPI 1013329846
$2,063.23
in general payments reported to CMS, 2019-2025
23 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $552 · 2022: $607 · 2023: $543 · 2024: $222 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $545.75 | 2021-2024 | Lifevest |
| Pfizer INC. | $202.65 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $159.73 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.02 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $134.95 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $97.00 | 2023 | Verquvo |
| Esperion Therapeutics, INC. | $92.67 | 2021-2022 | |
| Boston Scientific Corporation | $89.77 | 2024-2025 | Watchman Flx |
| Amgen INC. | $83.59 | 2021-2022 | |
| Philips North America LLC | $79.07 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $77.73 | 2021-2022 | |
| Abbott Laboratories | $57.08 | 2021-2023 | Aveir |
| Actelion Pharmaceuticals US, INC. | $51.58 | 2022-2023 | Opsumit |
| Galderma Laboratories, L.P. | $45.10 | 2025 | Dysport |
| Johnson & Johnson Health Care Systems INC. | $40.69 | 2023 | Uptravi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.51 | 2023 | Injectafer |
| Vital Connect, INC | $24.10 | 2023 | Vitalpatch Rtm |
| G Medical Diagnostic Services, INC. | $23.76 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.55 | 2023 | Inpefa |
| Medicomp INC | $19.32 | 2022 | |
| Novo Nordisk INC | $17.50 | 2025 | Wegovy |
| Abbvie INC. | $13.58 | 2024 | |
| Amarin Pharma, INC. | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Mullis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.